Director, Purification Development, Emerging Modalities
Alnylam Pharmaceuticals | |
paid time off
| |
United States, Massachusetts, Cambridge | |
675 West Kendall Street (Show on map) | |
May 05, 2026 | |
|
Overview: The Director, Purification Development, Emerging Modalities will provide technical leadership for purification development across novel modalities, with primary responsibility for antibody purification and close partnership with internal teams supporting antibody-oligonucleotide conjugate (AOC) programs. This individual will be responsible for developing robust, phase-appropriate purification processes to support early development, Phase I readiness, and transition into later-stage development. The role will lead purification strategy for antibody intermediates and work across internal and external teams to ensure purification approaches are practical, scalable, and aligned with program needs. The Director will partner closely with Research, Process Sciences, Analytical Development, Formulation Development, Regulatory, Technical Operations, Quality, and CDMO partners to support antibody-based and conjugate-related programs. This role will also contribute to regulatory CMC activities through authorship and review of technical documentation and by serving as a downstream subject matter expert in regulatory-facing discussions, as needed. This position requires sound scientific judgment, strong development experience, and the ability to convert technical complexity into clear plans, risks, and recommendations for cross-functional teams and senior leadership. Responsibilities:
Qualifications:
Preferred:
#LI-KB1 #LI-Hybrid U.S. Pay Range $191,700.00 - $259,300.00 The pay range reflects the full-time base salary range we expect to pay for this role at the time of posting. Base pay will be determined based on a number of factors including, but not limited to, relevant experience, skills, and education. This role is eligible for an annual short-term incentive award (e.g., bonus or sales incentive) and an annual long-term incentive award (e.g., equity). Alnylam's robust Total Rewards package is designed to support your overall health and well-being. We offer comprehensive benefits including medical, dental, and vision coverage, life and disability insurance, a lifestyle reimbursement program, flexible spending and health savings accounts and a 401(k)with a generous company match. Eligible employees enjoy paid time off, wellness days, holidays, and two company-wide recharge breaks. We also offer generous family resources and leave. Our commitment to your well-being reflects our belief that caring for our people fuels the impact we create together. Learn more about these and additional benefits offered by Alnylam by visiting the Benefits section of the Careers website: https://www.alnylam.com/careers AboutAlnylam We are the leader in RNAi therapeutics- a revolutionaryapproach with the potential to transform the lives of people with rare and common diseases. Built on Nobel Prize-winning science, Alnylam has delivered the breakthroughs that made RNAi therapeutics possibleand are just at the beginning of what's possible. Our deep pipeline, late-stage programs, and bold vision reflect our core values: fierce innovation, passion for excellence, purposeful urgency, open culture and commitment to people. We're proud to be a globally recognized top employer, wherean authentic, inclusive culture and breakthrough thinkingfuel one another. At Alnylam, we commit to an inclusive recruitment process and equal employment opportunity. Qualified applicants will receive consideration for employment without regard to their sex, gender or gender identity, sexual orientation, race, color, ethnicity, national origin, ancestry, citizenship, religion, creed, physical or mental disability, pregnancy status or related conditions, genetic information, veteran or military status, marital or familial status, political affiliation, age, or any other factor protected by federal, state, or local law. Alnylam is an E-Verify Employer. > | |
paid time off
May 05, 2026